Trial Profile
A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Lisocabtagene-maraleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms PILOT; TRANSCEND-NHL-006
- Sponsors Juno Therapeutics
- 12 Dec 2023 Results to assess post infusion monitoring-related HCRU identify from pooled TRANSFORM and PILOT studies, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results of analysis assessing HCRU and costs for managing CRS and/or NEs after liso-cel administration among patients with R/R large B-cell lymphoma (LBCL) treated with liso-cel as 2L therapy in two clinical studies: TRANSFORM and PILOT presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results of final analysis presented at the 65th American Society of Hematology Annual Meeting and Exposition